- Home
- ARMN vs DNTH Comparison
ARMN vs DNTH Comparison
Compare ARMN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- DNTH
- Stock Information
- Founded
- ARMN 1992
- DNTH 2015
- Country
- ARMN Canada
- DNTH United States
- Employees
- ARMN N/A
- DNTH N/A
- Industry
- ARMN
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- DNTH Health Care
- Exchange
- ARMN Nasdaq
- DNTH Nasdaq
- Market Cap
- ARMN 775.1M
- DNTH 823.1M
- IPO Year
- ARMN N/A
- DNTH N/A
- Fundamental
- Price
- ARMN $4.18
- DNTH $20.27
- Analyst Decision
- ARMN
- DNTH Strong Buy
- Analyst Count
- ARMN 0
- DNTH 8
- Target Price
- ARMN N/A
- DNTH $46.43
- AVG Volume (30 Days)
- ARMN 479.2K
- DNTH 291.2K
- Earning Date
- ARMN 11-12-2024
- DNTH 11-07-2024
- Dividend Yield
- ARMN N/A
- DNTH N/A
- EPS Growth
- ARMN N/A
- DNTH N/A
- EPS
- ARMN N/A
- DNTH N/A
- Revenue
- ARMN $484,511,000.00
- DNTH $5,366,000.00
- Revenue This Year
- ARMN $46.47
- DNTH $44.94
- Revenue Next Year
- ARMN N/A
- DNTH N/A
- P/E Ratio
- ARMN N/A
- DNTH N/A
- Revenue Growth
- ARMN 13.72
- DNTH 51.41
- 52 Week Low
- ARMN $2.60
- DNTH $6.58
- 52 Week High
- ARMN $5.16
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- ARMN 44.73
- DNTH 22.81
- Support Level
- ARMN $3.67
- DNTH $22.19
- Resistance Level
- ARMN $4.17
- DNTH $28.56
- Average True Range (ATR)
- ARMN 0.17
- DNTH 2.02
- MACD
- ARMN -0.01
- DNTH -0.88
- Stochastic Oscillator
- ARMN 52.04
- DNTH 3.38
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.